Protein Sciences and Partners Launch Health-At-Work to Bring Flublok® and Other Vaccines to the Workplace
MERIDEN, Conn., July 17, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that they have partnered with physicians from Velocity Urgent Care and launched a new initiative called Health-At-Work that offers on site influenza and other vaccinations to employers in Connecticut and surrounding regions. Unlike many vaccination providers, Health-At-Work offers the egg-free, highly pure Flublok influenza vaccine in the convenience of the employer's workplace. Employers can customize their clinics and can choose to offer single or multiple vaccinations as part of the same clinic. Billing is handled by Health-At-Work and most insurance is accepted.
"We are a Company dedicated to saving lives and promoting health through the creation of better, safer vaccines," said Manon Cox, President and CEO of Protein Sciences. "Health-At-Work is a way we are taking things a step further to make vaccination easy and convenient for improved health for the entire community."
"Based on the median income for the state of Connecticut, the average employer will lose $1,070 per employee due to flu-related illness this season," said Susan Manganello, Director of Medical Services at Protein Sciences. "Health-At-Work provides a seamless vaccination program that enables employers to improve the health and wellbeing of employees and save money for their businesses."
Protein Sciences will host a business networking breakfast that will feature the medical staff from Health-At-Work on Wednesday, July 23rd from 7:30-9:30am at 875 Research Parkway, Meriden, CT. To schedule a clinic, find out more about Health-At-Work, or if you plan to attend this event, contact Susan Manganello, RN at firstname.lastname@example.org.
About Protein Sciences
Protein Sciences is a vaccine development and protein production company that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals.
Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, was approved by FDA in January 2013. Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus or antibiotics in manufacturing. Flublok is highly purified and does not contain any preservatives (e.g., thimerosal, a mercury derivative), egg proteins, gelatin or latex. In addition, Flublok is triple the strength of conventional influenza vaccines. Flublok is a perfect copy of the virus coat and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al. (2014) PLOS ONE 9(3), e92153). We have filed for FDA approval of Flublok for ages 50 and above and expect to receive approval in time for the 2014/15 influenza season.
Healthcare professionals can order Flublok by contacting FFF Enterprises at 800-843-7477 or ASD Specialty Healthcare at 866-281-4FLU.
Flublok Safety Information
Flublok is approved for people 18-49 years old to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Other side effects may occur and include fatigue, headache and muscle aches.
Flublok should not be administered to anyone with a severe allergic reaction (e.g., anaphylaxis) to any vaccine component.
Tell the doctor if you have ever experienced Guillain-Barré syndrome (severe muscle weakness) within 6 weeks of receipt of a previous dose of influenza vaccine. If you notice any other problems or symptoms following vaccination, please contact your healthcare professional immediately. Vaccination with Flublok may not protect all individuals.
SOURCE Protein Sciences Corporation